Evommune raised approximately $30 million through a private placement of nearly 4.97 million shares at $6.04 per share, extending its cash runway into the second half of 2029. Concurrently, it entered an exclusive license agreement with Hinova Pharmaceuticals to develop and commercialize EVO570, an oral VAV1 molecular glue degrader for autoimmune diseases, outside Greater China. The deal includes a $30 million upfront payment ($20 million cash and warrants) and up to approximately $1.1 billion in potential development, regulatory, and commercial milestones, plus tiered royalties on net sales. Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases.
